Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 221 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )
Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )
Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )
Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )
Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )
Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )
Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )
J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )
Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MWTBcpRqdWmlcn;ibYFtKEG\|c3H5		MVSxPEBp	M3HaN2ROW09?	M4LaTWFvfGm2conwZY5we2:vYXygZYN1cX[rdImge4l1cCCHQ{WwJI9nKDBwMECyOUDPxE1?	NIPsWogzPDhyNUm0Oi=>
MCF7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXuwMlAyNTFyMDFOwG0>	MWK0PEBp	NUnm[IV6TE2VTx?=	MVPJR\|UxRTBwN{Og{txO	M4jWeFI{QDdzOUC0
HCT116	NHTVNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTxVpBjOC5yMT2xNFAh\|ryP	MWO0PEBp	MnG2SG1UVw>?	M{n2ZmlEPTB;MT6xOkDPxE1?	MkX4NlM5PzF7MES=
U87MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\vRVAvODFvMUCwJO69VQ>?	Mn\uOFghcA>?	NITnbplFVVOR	NVq5SpZbUUN3ME2xMlMzKM7:TR?=	MnTCNlM5PzF7MES=
HBC4	NFjqTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYmwMlAyNTFyMDFOwG0>	NH[2RnM1QCCq		NYfvdIduVG:pIFfJOVA:NThwNkGgUS=>	MVSyNlM{PjJ2Nh?=
BSY1	NYXDOpFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTrNE4xOS1zMECg{txO	NV\USGdzPDhiaB?=		NIC2b4tNd2diR1m1NF0uQC52ODDN	M3L3e\|IzOzN4MkS2
HBC5	NIiyNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4f0NlAvODFvMUCwJO69VQ>?	Mkf5OFghcA>?		M4HOOWxw\yCJSUWwQU04Njh5IF2=	MWmyNlM{PjJ2Nh?=
MCF7	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\QNE4xOS1zMECg{txO	Mke0OFghcA>?		NUfDSotkVG:pIFfJOVA:NThwMU[gUS=>	Mlq5NlI{OzZ{NE[=
MDA-MB-231	M3H3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCwMlAyNTFyMDFOwG0>	M{CxO\|Q5KGh?		MYfMc4chT0l3ME2tPE4xQSCP	MXSyNlM{PjJ2Nh?=
U251	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXewMlAyNTFyMDFOwG0>	NUTQ[4hmPDhiaB?=		MYTMc4chT0l3ME2tO{43PiCP	NFfUVYEzOjN\|NkK0Oi=>
SF268	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTZNE4xOS1zMECg{txO	MXO0PEBp		NYrFT4Z4VG:pIFfJOVA:NTdwOUKgUS=>	NVH0RWZnOjJ\|M{[yOFY>
SF295	NWruXINKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrpdoN[OC5yMT2xNFAh\|ryP	MmrTOFghcA>?		NHy4eXJNd2diR1m1NF0uQC5\|MTDN	NVTnVG9GOjJ\|M{[yOFY>
SF539	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLTSlRuOC5yMT2xNFAh\|ryP	NV\vfZIzPDhiaB?=		MW\Mc4chT0l3ME2tPE42QSCP	MYWyNlM{PjJ2Nh?=
SNB75	M4G1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlniNE4xOS1zMECg{txO	M13xW\|Q5KGh?		M1HMSmxw\yCJSUWwQU05NjV6IF2=	NYL3Rpg{OjJ\|M{[yOFY>
SNB78	NE\4Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrtNE4xOS1zMECg{txO	Ml\2OFghcA>?		NXXRd5JoVG:pIFfJOVA:NThwNkWgUS=>	MnTpNlI{OzZ{NE[=
HCC2998	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvtNHdCOC5yMT2xNFAh\|ryP	Mn\iOFghcA>?		M{W2Tmxw\yCJSUWwQU05NjB3IF2=	M3z2NlIzOzN4MkS2
KM12	M3PwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnrc29[OC5yMT2xNFAh\|ryP	NHX0T4c1QCCq		NEK5[pNNd2diR1m1NF0uPy53NDDN	MXGyNlM{PjJ2Nh?=
HT-29	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL6OmZvOC5yMT2xNFAh\|ryP	MYG0PEBp		MXfMc4chT0l3ME2tO{44PSCP	MYeyNlM{PjJ2Nh?=
HCT15	M4PONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\uWY5FOC5yMT2xNFAh\|ryP	Mn3IOFghcA>?		NVntSJBIVG:pIFfJOVA:NThwMEOgUS=>	Mm\ZNlI{OzZ{NE[=
HCT116	NH;t[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnENE4xOS1zMECg{txO	MkC0OFghcA>?		MYrMc4chT0l3ME2tO{43OSCP	MX[yNlM{PjJ2Nh?=
NCI-H23	NUnufJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjBNE4xOS1zMECg{txO	MmPyOFghcA>?		NYrJRVkzVG:pIFfJOVA:NTdwNkSgUS=>	MV:yNlM{PjJ2Nh?=
NCI-H226	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XhfFAvODFvMUCwJO69VQ>?	M2nPdVQ5KGh?		MmWwUI9oKEeLNUC9MVgvPDRiTR?=	NEDXRmQzOjN\|NkK0Oi=>
NCI-H522	NUXJ[IhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPuR3U6OC5yMT2xNFAh\|ryP	MXi0PEBp		NV65VVhZVG:pIFfJOVA:NThwNEWgUS=>	MXuyNlM{PjJ2Nh?=
NCI-H438	NVHNW3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonvNE4xOS1zMECg{txO	NWfWPG9pPDhiaB?=		MUXMc4chT0l3ME2tPE4yOSCP	MmPRNlI{OzZ{NE[=
A549	NFXmeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S2WlAvODFvMUCwJO69VQ>?	MoK1OFghcA>?		MY\Mc4chT0l3ME2tPE4xPyCP	NIH1dZkzOjN\|NkK0Oi=>
DMS273	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{C5blAvODFvMUCwJO69VQ>?	M4TBbFQ5KGh?		Mn7UUI9oKEeLNUC9MVcvQDBiTR?=	MlPLNlI{OzZ{NE[=
DMS114	M3rUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP2NE4xOS1zMECg{txO	M4C3XVQ5KGh?		NHz2Xo1Nd2diR1m1NF0uQC5\|OTDN	MXWyNlM{PjJ2Nh?=
LOXIMVI	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmwMlAyNTFyMDFOwG0>	NXXZdpRyPDhiaB?=		NFnrc3BNd2diR1m1NF0uQC54NjDN	MX:yNlM{PjJ2Nh?=
OVCAR3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnKdYQzOC5yMT2xNFAh\|ryP	MlvSOFghcA>?		MlH2UI9oKEeLNUC9MVgvOTdiTR?=	Mn3DNlI{OzZ{NE[=
OVCAR4	NUXTWY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjQTHBJOC5yMT2xNFAh\|ryP	MYq0PEBp		MVHMc4chT0l3ME2tPE42QCCP	NIO3cY4zOjN\|NkK0Oi=>
OVCAR5	M33wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvodJAxNjBzLUGwNEDPxE1?	NFPMOpE1QCCq		NV6ySW1OVG:pIFfJOVA:NTdwNUegUS=>	NYSwNGVJOjJ\|M{[yOFY>
OVCAR8	M4LUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;yNE4xOS1zMECg{txO	MXm0PEBp		MUfMc4chT0l3ME2tO{45PCCP	NGHTcHUzOjN\|NkK0Oi=>
SKOV3	NV;scZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LEVlAvODFvMUCwJO69VQ>?	NUDmcXk1PDhiaB?=		NUDTPWdMVG:pIFfJOVA:NThwNEGgUS=>	NYL2c\|RYOjJ\|M{[yOFY>
RXF631L	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELhc20xNjBzLUGwNEDPxE1?	MkjZOFghcA>?		Mn\MUI9oKEeLNUC9MVgvOjFiTR?=	M{nZRlIzOzN4MkS2
ACHN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnhXm0xNjBzLUGwNEDPxE1?	NInHenU1QCCq		M2rlSmxw\yCJSUWwQU04Njl3IF2=	MUmyNlM{PjJ2Nh?=
St-4	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fDRlAvODFvMUCwJO69VQ>?	MneyOFghcA>?		MV\Mc4chT0l3ME2tO{41PyCP	NVO0UIJlOjJ\|M{[yOFY>
MKN1	NFHvW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TaUVAvODFvMUCwJO69VQ>?	NFj0bIQ1QCCq		Mn7JUI9oKEeLNUC9MVgvPDFiTR?=	MmjrNlI{OzZ{NE[=
MKN7	NFXCN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;4TZMxNjBzLUGwNEDPxE1?	MV[0PEBp		Ml:4UI9oKEeLNUC9MVcvPjhiTR?=	MX2yNlM{PjJ2Nh?=
MKN28	M1PRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnhNE4xOS1zMECg{txO	MlTIOFghcA>?		NWDMOGRRVG:pIFfJOVA:NTdwMEegUS=>	MX2yNlM{PjJ2Nh?=
MKN45	M4\0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHafoQxNjBzLUGwNEDPxE1?	MUW0PEBp		M1T4NGxw\yCJSUWwQU05NjN2IF2=	MlnwNlI{OzZ{NE[=
MKN74	M1[3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ezVVAvODFvMUCwJO69VQ>?	MmjaOFghcA>?		NWLUcY5WVG:pIFfJOVA:NTdwNEKgUS=>	MWSyNlM{PjJ2Nh?=
DU145	NXfWZ2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[1O4wxNjBzLUGwNEDPxE1?	MYS0PEBp		NF;EXI5Nd2diR1m1NF0uQC5zNjDN	M4Oz[\|IzOzN4MkS2
PC3	NXnqO2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFWyXnUxNjBzLUGwNEDPxE1?	NGLlSIY1QCCq		MXzMc4chT0l3ME2tPE43PiCP	NIPtdGYzOjN\|NkK0Oi=>
Trypanosoma brucei brucei	NIXZfVFHfW6ldHnvckBCe3OjeR?=	M{LkNFIxOCCwTR?=	MUexNkBp	MoH3SG1UVw>?	M{X4dWRm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?	NF75XZEzPDhyNUm0Oi=>
Trypanosoma brucei brucei	NGXHR4hHfW6ldHnvckBCe3OjeR?=		M1nwbFE5KGh?	NFv1bXRFVVOR	MXHJcohq[mm2aX;uJI9nKHKnY3XweI9zNW2nZHnheIVlKGWwZH;jfZRwe2m\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHS{YX7z[oVzemmwIIXweIFs\Q>?	MkXBNlQ5ODV7NE[=
Trypanosoma brucei brucei	M3rTOmZ2dmO2aX;uJGF{e2G7	MYqyNFAhdk1?	MoC5NVIhcA>?	M1jSVmROW09?	Mor6SYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>	M{\RdVI1QDB3OUS2
Trypanosoma brucei brucei	MWDGeY5kfGmxbjDBd5NigQ>?	MVWyNFAhdk1?	MXexNkBp	NILUVVJFVVOR	M3LIN2Vn\mWldDDvckBxcG:\|cHjheIllgWylaH;sbY5mKGyndnXs	NFXXS2ozPDhyNUm0Oi=>
UM-UC-3	NFuwNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXJTWM2OD1\|MUWgdG0>	M2jHVHNCVkeHUh?=
SBC-1	NFn0ZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XyTmlEPTB;N{SyJJBO	NUjl[IRsW0GQR1XS
MKN1	NYXpOlhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUS3N\|hQUUN3ME2yMlghdk1?	M{jhTHNCVkeHUh?=
NCI-H720	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXFNmc5UUN3ME2zMlU4KG6P	M1;jVHNCVkeHUh?=
BFTC-909	NUmxZ4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHjTWM2OD1\|LkexJI5O	Mm\DV2FPT0WU
BPH-1	NXfHNpE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PWbmlEPTB;ND63OkBvVQ>?	NH2wNYNUSU6JRWK=
PC-3	MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTVwMEmgcm0>	MkD4V2FPT0WU
AN3-CA	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HkZmlEPTB;NT61OkBvVQ>?	NVLIWVNsW0GQR1XS
HN	NFewOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTVwOU[gcm0>	MlzwV2FPT0WU
HCC2218	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnP2TWM2OD14Lk[xJI5O	NWnCNYVpW0GQR1XS
KP-4	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vNUGlEPTB;NzDuUS=>	NH7kdVVUSU6JRWK=
LU-139	NULqXFd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\LOVBKUUN3ME23Mlc4KG6P	NWnjc\|M3W0GQR1XS
ETK-1	NVrHeJR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTdwOEigcm0>	NUW4TItoW0GQR1XS
Ramos-2G6-4C10	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDtTWM2OD16LkS5JI5O	NYWyO4pRW0GQR1XS
MHH-PREB-1	NUXhdnFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4f0WmlEPTB;OT6xNkBvVQ>?	Mmq2V2FPT0WU
DU-4475	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HzbWlEPTB;OT60OEBvVQ>?	MXvTRW5ITVJ?
NCI-H1666	NVrzcnp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjoUVFKSzVyPUmuO\|Ehdk1?	NITzR3NUSU6JRWK=
CAMA-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[zUmlEPTB;OT64JI5O	Mn\pV2FPT0WU
TYK-nu	M2nm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTlwOUSgcm0>	NYPhOVBKW0GQR1XS
MFE-280	M2rm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LDVGlEPTB;OT65PUBvVQ>?	NHXq[FhUSU6JRWK=
A549	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPWTWM2OD1zMD6xOEBvVQ>?	NEnvV\|lUSU6JRWK=
769-P	NELHcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jDOGlEPTB;MUCuOFQhdk1?	NVTjb3lkW0GQR1XS
L-363	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jDc2lEPTB;MUCuOlkhdk1?	Mm\PV2FPT0WU
ES8	M2qzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTFyLkmgcm0>	MWfTRW5ITVJ?
PA-1	NV7ZemJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDvUXJuUUN3ME2xNU45OiCwTR?=	NVfnZ2JsW0GQR1XS
Mewo	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjpfIRSUUN3ME2xNU46QSCwTR?=	M17rbnNCVkeHUh?=
HSC-3	M1PaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljWTWM2OD1zMj6yNUBvVQ>?	M{XnXXNCVkeHUh?=
H4	NWT5NJh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTF{Lk[3JI5O	NEXhVGNUSU6JRWK=
BB65-RCC	NXzJdW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoKwTWM2OD1zMj63NkBvVQ>?	NEnCNm9USU6JRWK=
NCI-H1793	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF{LkiyJI5O	MmW3V2FPT0WU
KARPAS-45	M{fGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTF\|LkWxJI5O	MoX6V2FPT0WU
GCT	NWLTZ3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTF\|Lk[4JI5O	MorEV2FPT0WU
EoL-1	M{PGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED4XVlKSzVyPUGzMlk{KG6P	MnPnV2FPT0WU
LB2241-RCC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmj5TWM2OD1zND6wNUBvVQ>?	MkfpV2FPT0WU
ES5	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XXfWlEPTB;MUSuO\|Qhdk1?	MmXlV2FPT0WU
LOXIMVI	NGXOeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrBW\|VKUUN3ME2xOE46QSCwTR?=	NHu3c5FUSU6JRWK=
COR-L105	MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTF3LkC0JI5O	MkDyV2FPT0WU
P12-ICHIKAWA	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\ZTFhqUUN3ME2xOU4yKG6P	MUPTRW5ITVJ?
CHL-1	M{i4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF3LkS1JI5O	NFj0ZotUSU6JRWK=
VMRC-RCZ	NXjvVIM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPncGFkUUN3ME2xOU43OyCwTR?=	NIHWcVFUSU6JRWK=
HH	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jB[2lEPTB;MUWuO{BvVQ>?	NF:zZlFUSU6JRWK=
NUGC-3	NHXrOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrmO4FKSzVyPUG2MlM1KG6P	Ml\yV2FPT0WU
EGI-1	NIT1S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLITWM2OD1zNj60N{BvVQ>?	M4DmfnNCVkeHUh?=
OS-RC-2	M1;Uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;qUHBKSzVyPUG2MlQ4KG6P	MmHyV2FPT0WU
MOLT-16	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4C4fGlEPTB;MUeuNVUhdk1?	NGj5c2hUSU6JRWK=
NCI-H209	M1;GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYL5U3VMUUN3ME2xO{4zQSCwTR?=	M3PkWHNCVkeHUh?=
697	M3y0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFr3SGVKSzVyPUG3MlQ{KG6P	NUKyfJNlW0GQR1XS
D-56MG	NIjjXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTF5Lk[5JI5O	M1XYcHNCVkeHUh?=
VA-ES-BJ	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j4RWlEPTB;MUeuPFMhdk1?	NH;neIJUSU6JRWK=
EW-16	M2nLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlOyTWM2OD1zOD6wOEBvVQ>?	NVPw[nJSW0GQR1XS
HGC-27	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NES5Z\|dKSzVyPUG4MlA3KG6P	NVjucXQzW0GQR1XS
ES7	MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTF6LkC5JI5O	NULx[5I1W0GQR1XS
HuH-7	NFP0T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml73TWM2OD1zOD60JI5O	MX3TRW5ITVJ?
BCPAP	NE\1dZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXDbHdKSzVyPUG4MlY2KG6P	NYXzZ2RWW0GQR1XS
SW1710	NFvuNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTsTWM2OD1zOD63NkBvVQ>?	NHTYPJlUSU6JRWK=
IST-MEL1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrLOYlNUUN3ME2xPE44PyCwTR?=	NHP5Om5USU6JRWK=
SF295	M{Hpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTF6LkmzJI5O	MX7TRW5ITVJ?
RPMI-7951	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33MSGlEPTB;MUmuNlghdk1?	M3HI[nNCVkeHUh?=
SF126	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHKdHlKSzVyPUG5MlQyKG6P	NGnWTpVUSU6JRWK=
GAMG	NEDPZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTPV3RxUUN3ME2xPU41QCCwTR?=	MXjTRW5ITVJ?
KNS-81-FD	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XQUmlEPTB;MUmuOVQhdk1?	NXjqflNlW0GQR1XS
RT-112	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4T2PWlEPTB;MUmuOlYhdk1?	NHPOdIRUSU6JRWK=
DEL	NIjHbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;VW\|JKSzVyPUKwMlQ6KG6P	NGf3WGxUSU6JRWK=
CGTH-W-1	NWi4R4o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXLTWM2OD1{MD62N{BvVQ>?	NUe0[lA{W0GQR1XS
HOS	NYX3cYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\nTWdZUUN3ME2yNU4xPiCwTR?=	M{f4O3NCVkeHUh?=
ES4	NHzmT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVX1TG93UUN3ME2yNU4xQCCwTR?=	MUXTRW5ITVJ?
RXF393	NUnlepFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTJzLkS1JI5O	MkTWV2FPT0WU
NCI-H2030	NF7wU\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnmbopKSzVyPUKxMlUzKG6P	MX7TRW5ITVJ?
YH-13	NUTqVYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWThRVYzUUN3ME2yNU45QCCwTR?=	M3vsUnNCVkeHUh?=
HT-1080	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4roZWlEPTB;MkGuPVMhdk1?	MlLZV2FPT0WU
NCI-SNU-1	M4e0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfOTWM2OD1{MT65OUBvVQ>?	MYPTRW5ITVJ?
G-402	NWXnTmJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DTfGlEPTB;MkKuNVYhdk1?	M3\ofHNCVkeHUh?=
786-0	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DjUGlEPTB;MkKuNlkhdk1?	M1z2Z3NCVkeHUh?=
ME-180	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLCTWM2OD1{Mj60N{BvVQ>?	MXTTRW5ITVJ?
NB69	M2D5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHLTWM2OD1{Mj61N{BvVQ>?	NEe0Vo5USU6JRWK=
J-RT3-T3-5	NYDOc5hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jIcWlEPTB;MkKuPVYhdk1?	M176OHNCVkeHUh?=
TGBC1TKB	NVe3bVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJ\|LkC1JI5O	M{i3UXNCVkeHUh?=
SW780	NXnq[HRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnJPJJKSzVyPUKzMlE{KG6P	MUfTRW5ITVJ?
MG-63	NV7P[o85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJ\|LkS1JI5O	NFTEVplUSU6JRWK=
BV-173	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvPR2RKSzVyPUKzMlg4KG6P	NUj2XnZEW0GQR1XS
CAL-51	NI\kUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jNVmlEPTB;MkOuPFkhdk1?	NXHNR3N4W0GQR1XS
A375	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\hd\|BtUUN3ME2yN{46OyCwTR?=	MY\TRW5ITVJ?
MEL-HO	NHLTTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHCb\|NKSzVyPUK0MlA1KG6P	MWnTRW5ITVJ?
EFO-27	NVXVdGI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nyS2lEPTB;MkSuN\|Mhdk1?	MkPBV2FPT0WU
Hs-578-T	NH76RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml22TWM2OD1{ND61PEBvVQ>?	MlK4V2FPT0WU
NBsusSR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\OTWM2OD1{ND62JI5O	Mnr3V2FPT0WU
CTB-1	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnoTWM2OD1{ND62O{BvVQ>?	MYPTRW5ITVJ?
FTC-133	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfNXZM6UUN3ME2yOU4yKG6P	MWjTRW5ITVJ?
MOLT-4	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfmTWM2OD1{NT6xNkBvVQ>?	MmPPV2FPT0WU
HO-1-N-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjCTW1KSzVyPUK1MlE2KG6P	M1vt[HNCVkeHUh?=
ES3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{POeWlEPTB;MkWuNlIhdk1?	M4nxVnNCVkeHUh?=
TI-73	NFLGenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjaTWM2OD1{NT6yPEBvVQ>?	MoT2V2FPT0WU
MPP-89	M1exT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHCe2RKSzVyPUK1MlMzKG6P	M2TkTHNCVkeHUh?=
KYSE-150	M363Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j6VGlEPTB;MkWuPFkhdk1?	MXjTRW5ITVJ?
LXF-289	NUTze5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXYTWM2OD1{Nj6wOEBvVQ>?	NHz0UG1USU6JRWK=
SK-LU-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTRTWM2OD1{Nj6xO{BvVQ>?	NEPHSnlUSU6JRWK=
HOP-92	NIX3fIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTJ4LkS4JI5O	M2XGV3NCVkeHUh?=
HuO9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPnTWM2OD1{Nj63OkBvVQ>?	MW\TRW5ITVJ?
SW962	NI\SfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XIVmlEPTB;Mk[uO\|Yhdk1?	MYXTRW5ITVJ?
RS4-11	M3[wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzRbXA{UUN3ME2yOk46OSCwTR?=	NHfpN3pUSU6JRWK=
NCI-H292	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:y[YRIUUN3ME2yO{BvVQ>?	MlP0V2FPT0WU
DB	M2m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;LTWM2OD1{Nz6zOkBvVQ>?	NH62RmdUSU6JRWK=
SW1088	NHzicG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj0TWM2OD1{OD6yPUBvVQ>?	NFjuXJdUSU6JRWK=
A204	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLJeW1KSzVyPUK4MlQ4KG6P	MlHKV2FPT0WU
A3-KAW	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJ6Lk[0JI5O	NWDTdoFwW0GQR1XS
MV-4-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjnTHVbUUN3ME2yPE44KG6P	NHzPWVZUSU6JRWK=
ES1	NUj1NYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjmWVM3UUN3ME2yPE45PCCwTR?=	NIDkSFBUSU6JRWK=
ONS-76	NFHhZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm2TWM2OD1{OT6wOUBvVQ>?	MlLiV2FPT0WU
D-263MG	NGfHeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\OTWM2OD1{OT6zOUBvVQ>?	M3HnenNCVkeHUh?=
U-2-OS	NITweldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHy0e4NKSzVyPUK5MlUhdk1?	M2fvfXNCVkeHUh?=
T98G	NEKxPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYT6NIZuUUN3ME2yPU45QCCwTR?=	MonxV2FPT0WU
GI-ME-N	NIPlOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJ7LkmxJI5O	NIG4UGpUSU6JRWK=
BHT-101	NF;KOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnwTm9OUUN3ME2zNE4xPSCwTR?=	MoT3V2FPT0WU
NOS-1	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoqyTWM2OD1\|MD6xNkBvVQ>?	MnjRV2FPT0WU
AsPC-1	NFvOT\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXr1V5FpUUN3ME2zNE4zKG6P	MnfLV2FPT0WU
QIMR-WIL	M{HOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTNyLk[gcm0>	NFzHRXhUSU6JRWK=
JVM-3	M4fqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PKbGlEPTB;M{CuPFMhdk1?	MofHV2FPT0WU
KU-19-19	NILDRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTNzLkGzJI5O	M2XvSXNCVkeHUh?=
OVCAR-8	M4nqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j1XmlEPTB;M{GuNlYhdk1?	NYexdHBEW0GQR1XS
BEN	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXkU4hrUUN3ME2zNU43OyCwTR?=	M4TwSXNCVkeHUh?=
BE-13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrIXHY4UUN3ME2zNU45OiCwTR?=	NWnWRm01W0GQR1XS
EW-18	NFHCOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXRVXhXUUN3ME2zNU45PiCwTR?=	MkjEV2FPT0WU
ECC10	M2raRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTNzLkm1JI5O	MV7TRW5ITVJ?
CTV-1	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXn5T4pPUUN3ME2zNk45OiCwTR?=	M{T2NnNCVkeHUh?=
COLO-800	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XVW2lEPTB;M{KuPVIhdk1?	MleyV2FPT0WU
A2058	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTN\|LkK1JI5O	NHHLc2xUSU6JRWK=
VM-CUB-1	M4[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXuTJZKSzVyPUOzMlQ{KG6P	NY\TXXdvW0GQR1XS
Ca9-22	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXiZ3dDUUN3ME2zN{42PSCwTR?=	NEjsN3lUSU6JRWK=
COLO-684	NFLZdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2juWWlEPTB;M{OuOVghdk1?	NHPmTolUSU6JRWK=
RPMI-8226	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\5So1TUUN3ME2zN{45OiCwTR?=	NVTQbmxvW0GQR1XS
SK-NEP-1	NWH0OXJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrsTWM2OD1\|ND6xOUBvVQ>?	M{PVfXNCVkeHUh?=
Becker	NGTWO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTN2LkKxJI5O	NF;QO\|RUSU6JRWK=
NCI-H28	NX3NWWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTN2LkS0JI5O	MYDTRW5ITVJ?
CAL-120	M4fGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTQPWFKSzVyPUO0MlczKG6P	NYnwN3NFW0GQR1XS
MDA-MB-157	NYPIO4JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTacGdLUUN3ME2zOU41OSCwTR?=	NWTBflFoW0GQR1XS
OVCAR-5	NV3KR5puT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGSxNlNKSzVyPUO1MlQ4KG6P	NFjkVVhUSU6JRWK=
LAMA-84	M4TIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnxTWM2OD1\|NT64O{BvVQ>?	NVX1So57W0GQR1XS
CAKI-1	NXTEVZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTN4LkSzJI5O	NXi4eIZ2W0GQR1XS
Daoy	NVm4e5k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jq[2lEPTB;M{[uO{BvVQ>?	NVrCTmU2W0GQR1XS
CAL-62	NVjFeHVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLETWM2OD1\|Nj64OkBvVQ>?	NHzZOI9USU6JRWK=
8-MG-BA	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTN5LkK1JI5O	M4[5TnNCVkeHUh?=
8505C	NILMOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\VVWlEPTB;M{euOVEhdk1?	M1;KTXNCVkeHUh?=
LNCaP-Clone-FGC	M3X6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHFXpF4UUN3ME2zO{42QSCwTR?=	M13NWXNCVkeHUh?=
CAL-39	NXfTWnlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7ZWW9KSzVyPUO3Mlkhdk1?	NUjDeo1qW0GQR1XS
MN-60	NGHaVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonFTWM2OD1\|Nz65OkBvVQ>?	MnLKV2FPT0WU
RKO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjPdJFKSzVyPUO4MlM{KG6P	MVzTRW5ITVJ?
U251	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mne3TWM2OD1\|OD60N{BvVQ>?	NUDUcW8{W0GQR1XS
SJSA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTN6LkW0JI5O	NEjFVoxUSU6JRWK=
CAL-12T	M3;yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXL2SVJMUUN3ME2zPE43KG6P	NFLBZ3NUSU6JRWK=
HCC1419	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTyPGJ6UUN3ME2zPE44OSCwTR?=	MkLWV2FPT0WU
CO-314	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGybJdpUUN3ME2zPE44PCCwTR?=	MV3TRW5ITVJ?
LB1047-RCC	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\PTWM2OD1\|OD64NUBvVQ>?	M2P4W3NCVkeHUh?=
A101D	NIDyT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXGbZJKSzVyPUO4Mlk4KG6P	MmLkV2FPT0WU
MDA-MB-175-VII	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjzUopsUUN3ME2zPU42OSCwTR?=	M4HWSXNCVkeHUh?=
MZ2-MEL	NUjXNpdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTN7Lk[2JI5O	MX7TRW5ITVJ?
NB5	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjQ[3JKSzVyPUSwMlY1KG6P	M3fXdnNCVkeHUh?=
G-401	NYPOWpJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1THRmlEPTB;NECuPFIhdk1?	NIX2SHZUSU6JRWK=
HT	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTRzLkCyJI5O	MoHIV2FPT0WU
8305C	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[yR2lEPTB;NEGuPFchdk1?	MUHTRW5ITVJ?
BHY	NXO3b49jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTR{LkeyJI5O	NUL2bXV2W0GQR1XS
NTERA-S-cl-D1	M4TYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHKSm5KSzVyPUSzJI5O	NIq1dpVUSU6JRWK=
T-24	NHnJZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTR\|LkizJI5O	MkKzV2FPT0WU
EPLC-272H	NYrRRYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z3PWlEPTB;NESuN\|khdk1?	MWnTRW5ITVJ?
PSN1	NGiwRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7HTWM2OD12ND60JI5O	NEfOPJRUSU6JRWK=
NCI-H2452	NVS3VZVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrpTWM2OD12ND61PEBvVQ>?	MULTRW5ITVJ?
KS-1	NEHOR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTR2Lk[2JI5O	NVn1Nos5W0GQR1XS
HD-MY-Z	NInrXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHLSXJKSzVyPUS0MlkzKG6P	MWrTRW5ITVJ?
KNS-62	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlW5TWM2OD12NT6zPEBvVQ>?	MVPTRW5ITVJ?
NOMO-1	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISyU2JKSzVyPUS1Mlg4KG6P	MUTTRW5ITVJ?
SK-HEP-1	M{j2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLrTWM2OD12Nj6wOEBvVQ>?	NGH0[oJUSU6JRWK=
IGR-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXh[oVKSzVyPUS2MlE{KG6P	NFn3U3hUSU6JRWK=
KYSE-180	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLSXGlWUUN3ME20Ok4yPyCwTR?=	MoLjV2FPT0WU
EW-22	NUDrR49lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTR4LkKgcm0>	NXjjU5NQW0GQR1XS
NCI-H1355	NIWzWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHtTWM2OD12Nj6zOEBvVQ>?	NXPHeWwyW0GQR1XS
DOHH-2	NGX2U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDRUll[UUN3ME20Ok4{PyCwTR?=	M1e4enNCVkeHUh?=
A4-Fuk	M1vzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nneGlEPTB;NE[uOVIhdk1?	MVTTRW5ITVJ?
PC-14	NYX3V3BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzYTo1KSzVyPUS2MlU4KG6P	NF3HfmxUSU6JRWK=
TE-5	NX3qS4lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX3TWM2OD12Nj64OEBvVQ>?	M13nRXNCVkeHUh?=
LB996-RCC	M3\Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnSTWM2OD12Nz6xPUBvVQ>?	MXTTRW5ITVJ?
NCI-H1623	NIWzU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTITnBKSzVyPUS3Mlc3KG6P	NUC2Z\|hkW0GQR1XS
NCI-H1155	M3jidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7oNI9KSzVyPUS4MlMzKG6P	M1nlW3NCVkeHUh?=
LoVo	NI\tUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm4TWM2OD12OD60JI5O	MVHTRW5ITVJ?
MCF7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3ZTWM2OD12OD61PEBvVQ>?	M4HlOnNCVkeHUh?=
AGS	NIfpSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTR6Lke3JI5O	Mn:0V2FPT0WU
PFSK-1	M12ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTtSHRlUUN3ME20PU4xPiCwTR?=	M16xVHNCVkeHUh?=
22RV1	M37TPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\HTWM2OD12OT6wPUBvVQ>?	M4LScHNCVkeHUh?=
COR-L23	NFvM[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHDTWM2OD12OT6xOkBvVQ>?	NUfEcJhJW0GQR1XS
D-283MED	NVfKNYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HPWWlEPTB;NEmuOlEhdk1?	Ml61V2FPT0WU
SW982	NVG4SVJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Pye2lEPTB;NEmuPVEhdk1?	NVX2em9GW0GQR1XS
SW620	NGCwXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTVyLkO2JI5O	NVjNWW1uW0GQR1XS
KYSE-140	NVPrd3VvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTVyLkW1JI5O	NXna[VFOW0GQR1XS
GCIY	M1zaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrqTIJKSzVyPUWwMlY4KG6P	NEDzPItUSU6JRWK=
MHH-ESS-1	NHP2fZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTVzLkm1JI5O	NGH2PYJUSU6JRWK=
D-423MG	NInoWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTV{LkC4JI5O	NGi3RmtUSU6JRWK=
SF539	NGj1fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTV{LkO1JI5O	MlruV2FPT0WU
RPMI-2650	NHnKNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr6WYZKSzVyPUWyMlY6KG6P	MoXjV2FPT0WU
GR-ST	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\NTWM2OD13Mj64O{BvVQ>?	MYrTRW5ITVJ?
YKG-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTV\|IH7N	M2rkeXNCVkeHUh?=
SK-MES-1	M1jpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTV\|LkK2JI5O	M1vCNXNCVkeHUh?=
HLE	NVnrXpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTPTWM2OD13Mz60O{BvVQ>?	MkjWV2FPT0WU
RVH-421	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37kV2lEPTB;NUOuOlchdk1?	NHTTbphUSU6JRWK=
C32	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTV\|LkizJI5O	NVHGOIFGW0GQR1XS
GB-1	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzUTWM2OD13ND6yJI5O	MXvTRW5ITVJ?
SNB75	M2fJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHHeHhKSzVyPUW0MlI3KG6P	MnjlV2FPT0WU
EM-2	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLy[ohlUUN3ME21OE41KG6P	MVTTRW5ITVJ?
RH-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPzOoJvUUN3ME21OE44KG6P	MXHTRW5ITVJ?
NKM-1	M4rPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e2SmlEPTB;NUSuPFEhdk1?	NGnq[XBUSU6JRWK=
NCI-H2405	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnf5TWM2OD13ND64PEBvVQ>?	MY\TRW5ITVJ?
KYSE-450	M2XpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jVU2lEPTB;NUWuNVYhdk1?	NEHHfY1USU6JRWK=
A704	NYnl[3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHFTWM2OD13NT61PUBvVQ>?	MlixV2FPT0WU
HAL-01	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljZTWM2OD13NT64N{BvVQ>?	NIPnfJlUSU6JRWK=
TE-11	NUXvR3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jlbGlEPTB;NUWuPVkhdk1?	NUTaZZJEW0GQR1XS
DOK	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLXTWM2OD13Nj6wNkBvVQ>?	MmX6V2FPT0WU
KY821	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPnT5NKSzVyPUW2MlIhdk1?	NHexNVRUSU6JRWK=
KGN	M1\HR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrhbXdIUUN3ME21Ok4{OiCwTR?=	NEH2dJlUSU6JRWK=
MC116	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjmXldvUUN3ME21O{45KG6P	MkXVV2FPT0WU
PANC-08-13	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrpdpFKSzVyPUW4MlAyKG6P	MVfTRW5ITVJ?
KE-37	NFq5VnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDxWpM5UUN3ME21PE44PyCwTR?=	MVXTRW5ITVJ?
KYSE-410	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1i2NmlEPTB;NUmuOFchdk1?	NXfySml3W0GQR1XS
RO82-W-1	M{TaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X6WWlEPTB;NUmuPUBvVQ>?	MkLmV2FPT0WU
M14	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ziNGlEPTB;NkCuNFQhdk1?	MXrTRW5ITVJ?
GI-1	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFmydIxKSzVyPU[wMlMhdk1?	NGDHW5VUSU6JRWK=
ML-2	NV6yZmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrrTWM2OD14MD62NkBvVQ>?	NGPNbHlUSU6JRWK=
BFTC-905	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTZyLk[1JI5O	MnTyV2FPT0WU
DMS-273	NF\Ye3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXPUmhKSzVyPU[wMlg4KG6P	NIOxbWdUSU6JRWK=
MDA-MB-361	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[5dIF[UUN3ME22NUBvVQ>?	M3jUenNCVkeHUh?=
MSTO-211H	M4\hZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV20UJdlUUN3ME22N{42OSCwTR?=	NVzZeZRTW0GQR1XS
MEG-01	M4jwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTZ\|LkWyJI5O	M4\RVXNCVkeHUh?=
M059J	NIP0Xm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\Mb5lKSzVyPU[zMlU5KG6P	MoOyV2FPT0WU
LN-405	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W1bWlEPTB;NkOuPFUhdk1?	MlzLV2FPT0WU
NCI-H1581	NYDzUFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDScFBKSzVyPU[0MlA{KG6P	NHL2ZZhUSU6JRWK=
TCCSUP	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rQcGlEPTB;NkSuOVMhdk1?	MUTTRW5ITVJ?
SW872	M{OySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf5[GtHUUN3ME22OE42PyCwTR?=	NYXr[4JSW0GQR1XS
KYSE-510	M2rk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDVTWM2OD14NT63OUBvVQ>?	MmfKV2FPT0WU
NCI-H1792	NXjL[5lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFy5S2FKSzVyPU[2MlE2KG6P	NWnndZU{W0GQR1XS
SW13	NYj5[Yw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nsSmlEPTB;Nk[uOUBvVQ>?	NH[4c29USU6JRWK=
TE-8	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1uzPWlEPTB;Nk[uOVIhdk1?	MWTTRW5ITVJ?
SCH	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;WcWlEPTB;NkeuNUBvVQ>?	MnGxV2FPT0WU
NEC8	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zEeWlEPTB;NkeuNlQhdk1?	NXfncVVWW0GQR1XS
HuO-3N1	NFfVOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorjTWM2OD14Nz6zNUBvVQ>?	NGXWd4tUSU6JRWK=
EFM-19	NF;zSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXsZW9sUUN3ME22O{42KG6P	NFqycm1USU6JRWK=
HEC-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHod\|lMUUN3ME22O{42OiCwTR?=	NWLTW\|RlW0GQR1XS
T47D	NXXCb4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTZ5Lki3JI5O	M3[yNHNCVkeHUh?=
SNU-423	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTZ5Lkm4JI5O	NUC1UHRkW0GQR1XS
WM-115	M2TEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7ZcZVWUUN3ME22PE4yPCCwTR?=	NYjsNndCW0GQR1XS
CaR-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LrfmlEPTB;NkiuNlUhdk1?	NH3rTplUSU6JRWK=
KU812	NEDtOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\tXI86UUN3ME22PE43QSCwTR?=	MWnTRW5ITVJ?
AM-38	NWXZUGttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPhTWM2OD14OT6zNUBvVQ>?	MlizV2FPT0WU
KOSC-2	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljsTWM2OD14OT65O{BvVQ>?	NV7Z[VBJW0GQR1XS
MC-IXC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTdyLkC4JI5O	NWf6fWtCW0GQR1XS
SCC-4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHsToNKSzVyPUexMlM5KG6P	Mn24V2FPT0WU
Calu-3	NX\y[2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTdzLkm4JI5O	Mnv2V2FPT0WU
RPMI-8866	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTd{LkiyJI5O	M4Wxb3NCVkeHUh?=
OVCAR-4	M{TUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPkTWM2OD15Mz6zOkBvVQ>?	MX7TRW5ITVJ?
OAW-42	NY\SOINxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXaSGRHUUN3ME23N{4{QSCwTR?=	NYf0TIs3W0GQR1XS
ATN-1	M1LBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHniTZRKSzVyPUezMlg4KG6P	MmLGV2FPT0WU
CHP-212	NHXSdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7m[GFxUUN3ME23OE46PSCwTR?=	NV3wNIozW0GQR1XS
C2BBe1	M4LFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTd3LkCzJI5O	MUTTRW5ITVJ?
A498	MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX36eoVlUUN3ME23OU4yPSCwTR?=	MnXzV2FPT0WU
SH-4	NYL0e2dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTd3LkKxJI5O	M4Tk[nNCVkeHUh?=
SNU-449	NXe0[2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn4NJZTUUN3ME23OU44QSCwTR?=	NW[2[ZVDW0GQR1XS
RD	NFnacY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfWVHNKSzVyPUe1Mlg3KG6P	M{nDcXNCVkeHUh?=
PANC-03-27	NWnjW2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3:wcGlEPTB;N{[uNlUhdk1?	MWHTRW5ITVJ?
S-117	NHrqR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTd4LkK3JI5O	MVXTRW5ITVJ?
SK-MEL-2	NXfMXpBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTd4Lke1JI5O	NFH5dYlUSU6JRWK=
LK-2	NGXNVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTd5LkC1JI5O	M2PxXXNCVkeHUh?=
CP50-MEL-B	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\mSWlEPTB;N{euOEBvVQ>?	M2DXZXNCVkeHUh?=
647-V	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzubmRXUUN3ME23PE4xPyCwTR?=	M{e4OnNCVkeHUh?=
LU-134-A	NGDmXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[3TWM2OD15OT6wN{BvVQ>?	M1TGNXNCVkeHUh?=
5637	NYLxfJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;p[XNKSzVyPUe5MlI{KG6P	NGX0XmVUSU6JRWK=
NCI-H1437	NF\TfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULETm97UUN3ME24NE42KG6P	NWGxcHlJW0GQR1XS
NCI-H460	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRThzLkKzJI5O	M3LtRXNCVkeHUh?=
BxPC-3	NXvYc2wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7YdFNKSzVyPUixMlQ3KG6P	M2S2eXNCVkeHUh?=
CAN	M17zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRThzLki0JI5O	NH\Jb2xUSU6JRWK=
KINGS-1	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHiVGxKSzVyPUiyMlMzKG6P	M4DO[3NCVkeHUh?=
OCUB-M	NIPNPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fmPWlEPTB;OEKuOFEhdk1?	MlvSV2FPT0WU
KALS-1	NWXVe5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkW2TWM2OD16Mj61OEBvVQ>?	MnyyV2FPT0WU
OCI-AML2	M3LP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTh{Lk[xJI5O	NFjUPVJUSU6JRWK=
A253	M{jXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zifmlEPTB;OEKuOlUhdk1?	MlWzV2FPT0WU
LCLC-97TM1	NILmPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfrWmRKSzVyPUiyMlg3KG6P	NEKwU2xUSU6JRWK=
NCI-H520	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTh\|LkC2JI5O	MYTTRW5ITVJ?
P30-OHK	NHHkdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7BR4tKSzVyPUizMlUhdk1?	M2jNbHNCVkeHUh?=
SBC-5	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTh\|LkWyJI5O	NITxfZJUSU6JRWK=
HCE-T	M4LOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTRUoxqUUN3ME24N{44PCCwTR?=	MV;TRW5ITVJ?
JEG-3	M1LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULYbZl4UUN3ME24OE4yKG6P	NX2zU\|NEW0GQR1XS
KG-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m1N2lEPTB;OESuNlQhdk1?	Mlf6V2FPT0WU
MIA-PaCa-2	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXj1XYJJUUN3ME24OE42PCCwTR?=	MkPYV2FPT0WU
CAL-33	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPtTWM2OD16NT6wPEBvVQ>?	MkfQV2FPT0WU
639-V	M3;Jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHK1TIlKSzVyPUi1MlQzKG6P	MlfxV2FPT0WU
NCI-H1048	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnZOFJvUUN3ME24Ok4{OSCwTR?=	M4jM[nNCVkeHUh?=
NCI-H1573	NEXJRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzPTWxKSzVyPUi3MlQ5KG6P	NW\ZVJRlW0GQR1XS
NCI-H2228	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTh6LkK2JI5O	MmPoV2FPT0WU
NB14	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEexfWlKSzVyPUi4MlMhdk1?	NVrJdmM5W0GQR1XS
SCC-25	NF2wO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzlOGZsUUN3ME24PU45OiCwTR?=	NETrfYZUSU6JRWK=
A431	M{nmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmW3TWM2OD16OT65O{BvVQ>?	MoPUV2FPT0WU
SN12C	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTlyLk[yJI5O	M{jFcnNCVkeHUh?=
HuCCT1	NUDKTYJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkG3TWM2OD17MD63OkBvVQ>?	MlTnV2FPT0WU
LS-123	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXLTWM2OD17Mj6xPEBvVQ>?	M2PTNHNCVkeHUh?=
CAL-85-1	NIHSeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGT1Z45KSzVyPUmyMlQ5KG6P	NV7rTlFHW0GQR1XS
ES6	M{SwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnraTWM2OD17Mj64N{BvVQ>?	NGL4cHVUSU6JRWK=
NCI-H650	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHHTWM2OD17ND6wPUBvVQ>?	M{focnNCVkeHUh?=
NCI-H446	NXz5eGVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TtUGlEPTB;OUWuNVIhdk1?	Ml\pV2FPT0WU
EW-13	NGHFZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP1TWM2OD17NT63OUBvVQ>?	MkPJV2FPT0WU
HSC-2	NWjjT2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzmTWM2OD17NT64PUBvVQ>?	MWnTRW5ITVJ?
U031	M3T1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTDTWM2OD17Nj63N{BvVQ>?	NXflUYNSW0GQR1XS
EW-11	M3flNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TUTWlEPTB;OU[uPFghdk1?	NYfDZZlQW0GQR1XS
GAK	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojjTWM2OD17OD65N{BvVQ>?	M1u2TnNCVkeHUh?=
SK-OV-3	M4jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjEU4liUUN3ME2xNFAvODdibl2=	NI\CT5VUSU6JRWK=
OMC-1	M3v1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTFyMD6xPEBvVQ>?	M1;xdHNCVkeHUh?=
TK10	NIm2coJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrFbnZEUUN3ME2xNFAvOjFibl2=	M131cHNCVkeHUh?=
EKVX	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTFyMD62JI5O	MmW2V2FPT0WU
Detroit562	M2XVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LCbGlEPTB;MUCyMlE4KG6P	M2D1ZnNCVkeHUh?=
SF268	NF[zZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFv2eJhKSzVyPUGwNk4{PCCwTR?=	M2\KcnNCVkeHUh?=
SNU-387	M2DiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlK2TWM2OD1zMESuNVchdk1?	NUjERWM{W0GQR1XS
MDA-MB-231	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFSycHBKSzVyPUGwOU4xPiCwTR?=	NUHpPVN2W0GQR1XS
NCI-H1563	NWLreFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfLO\|JKSzVyPUGwOU4yQCCwTR?=	M1nNbnNCVkeHUh?=
D-502MG	M2ni[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFyNT63JI5O	NH;PUYJUSU6JRWK=
A2780	M3nkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TRfmlEPTB;MUC2MlQ4KG6P	M3\tbnNCVkeHUh?=
IA-LM	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHtdIhKSzVyPUGwO{42OSCwTR?=	NFnuTlZUSU6JRWK=
D-392MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFyNz61OEBvVQ>?	NE\XOlFUSU6JRWK=
MS-1	NGHlXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnZOYZZUUN3ME2xNFcvPzFibl2=	NUX3bnZkW0GQR1XS
SW1990	M4TzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\aXGlEPTB;MUC4MlU1KG6P	NWq0W3ptW0GQR1XS
HEL	M3rRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWKwb2U1UUN3ME2xNFkvOjlibl2=	MW\TRW5ITVJ?
SW1573	M3[5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXOVHRKSzVyPUGwPU4{OSCwTR?=	MWnTRW5ITVJ?
SW1783	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;FVGlEPTB;MUGwMlIzKG6P	Mn\oV2FPT0WU
COLO-680N	NIHjRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnqxTWM2OD1zMUCuO\|Yhdk1?	MnzMV2FPT0WU
NCI-N87	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDOS3BKSzVyPUGxNU4xPCCwTR?=	MXfTRW5ITVJ?
SK-MEL-28	M3zPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTFzMT61OUBvVQ>?	NWOyRlRPW0GQR1XS
BT-20	NYjaXHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1T5OGlEPTB;MUGyMlAyKG6P	MmW4V2FPT0WU
NCI-H1648	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLqTWM2OD1zMUOgcm0>	MXvTRW5ITVJ?
no-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrheVNoUUN3ME2xNVMvOjhibl2=	NXL2cJFtW0GQR1XS
MOLT-13	NFzPWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PSVGlEPTB;MUGzMlQ1KG6P	MlPzV2FPT0WU
NCI-H2170	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzxVoFxUUN3ME2xNVQvPTFibl2=	M1XoN3NCVkeHUh?=
HTC-C3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HRV2lEPTB;MUG2Mlg2KG6P	M4LJT3NCVkeHUh?=
LU-99A	NWnXNoF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFzNz6yNUBvVQ>?	M4npbHNCVkeHUh?=
HCC2998	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFzNz65NkBvVQ>?	M37IPHNCVkeHUh?=
NB13	NX[4To5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFzNz65PUBvVQ>?	MYfTRW5ITVJ?
GT3TKB	NE[yN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7Db3pYUUN3ME2xNVgvODhibl2=	MXjTRW5ITVJ?
BT-549	NUj5[VI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHsTWM2OD1zMUiuPVUhdk1?	MoHkV2FPT0WU
NCI-H747	NWTEOZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKyTpExUUN3ME2xNVkvOzRibl2=	MYjTRW5ITVJ?
EW-1	M2PIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XUfWlEPTB;MUKwMlIhdk1?	MUnTRW5ITVJ?
LB831-BLC	M{HBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vWbWlEPTB;MUKwMlY{KG6P	MWPTRW5ITVJ?
NMC-G1	NV3o[IJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF{MT6xNUBvVQ>?	M3jWTXNCVkeHUh?=
COLO-679	NW\tdo05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrSPWpQUUN3ME2xNlIvOTVibl2=	NWTJ[FhHW0GQR1XS
HL-60	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz0TWM2OD1zMkOuNUBvVQ>?	MnL3V2FPT0WU
MKN7	MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFn2e2xKSzVyPUGyN{45OyCwTR?=	MV;TRW5ITVJ?
RERF-LC-MS	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W2XWlEPTB;MUK0MlMyKG6P	MmrMV2FPT0WU
DMS-114	NYDzbHRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDtTWM2OD1zMkWuNFkhdk1?	MVLTRW5ITVJ?
HuP-T4	NEjHRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mor1TWM2OD1zMk[uPVchdk1?	NGTCUm1USU6JRWK=
HCC2157	NH7TVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF{Nz61JI5O	MlrlV2FPT0WU
SKG-IIIa	NWXPeXRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NES4eIVKSzVyPUGyPE45KG6P	Mn3hV2FPT0WU
HCT-116	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[5XWtGUUN3ME2xN\|AvPjRibl2=	NXXZSnp1W0GQR1XS
BB30-HNC	NWXHS2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\GXllKSzVyPUGzNE44QCCwTR?=	NEXoV\|BUSU6JRWK=
KYSE-270	M4[0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjJTWM2OD1zM{CuPFghdk1?	MYnTRW5ITVJ?
MFM-223	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zsXmlEPTB;MUOxMlUyKG6P	NFjhRmtUSU6JRWK=
NH-12	NV7zXWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF\|Mj65PUBvVQ>?	MYjTRW5ITVJ?
U-118-MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG3b5FKSzVyPUGzN{43OiCwTR?=	MkPIV2FPT0WU
ESS-1	NVTVW3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17BV2lEPTB;MUO1MlE5KG6P	MVrTRW5ITVJ?
D-247MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTLTWM2OD1zM{WuNlEhdk1?	MW\TRW5ITVJ?
IGROV-1	NG\UbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XYNmlEPTB;MUO1Mlc3KG6P	NFXxPHVUSU6JRWK=
C-33-A	NWXOR2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTF\|NT65O{BvVQ>?	MmCwV2FPT0WU
NCI-H1693	MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LQS2lEPTB;MUO2MlEzKG6P	NU\5eJhFW0GQR1XS
MLMA	NGfCVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HWNWlEPTB;MUO2MlU5KG6P	MVTTRW5ITVJ?
SK-N-AS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TTSWlEPTB;MUO3MlE4KG6P	NGK0fmlUSU6JRWK=
NCI-H1755	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTF\|OD64OUBvVQ>?	NVHnOXZZW0GQR1XS
CHP-134	NIDUWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jxXWlEPTB;MUO5MlU2KG6P	MYXTRW5ITVJ?
LS-513	NX7FS5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTF2MD65NUBxVQ>?	NV;pOY9ZW0GQR1XS
TE-12	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTF2MD65N{BvVQ>?	MXTTRW5ITVJ?
KNS-42	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTFTWM2OD1zNESuN{BvVQ>?	MUnTRW5ITVJ?
SJRH30	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUj1TlVsUUN3ME2xOFQvPDRibl2=	M1rL[nNCVkeHUh?=
NCI-H1092	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DwfGlEPTB;MUS0MlUzKG6P	M4HY[HNCVkeHUh?=
H-EMC-SS	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH33Z\|FKSzVyPUG0Ok45OSCwTR?=	NUTUZ21pW0GQR1XS
SK-MEL-3	M{SyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHvTWM2OD1zNEeuOVUhdk1?	NH3SdnhUSU6JRWK=
SK-N-FI	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLLOIsxUUN3ME2xOFcvPTlibl2=	NGLUeVBUSU6JRWK=
NCI-H2126	NUTKe4dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[1S2Q4UUN3ME2xOFgvOTVibl2=	MVPTRW5ITVJ?
NCI-H1299	NVj3SnQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF3MD6yNkBvVQ>?	MoDjV2FPT0WU
CFPAC-1	M4HmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF71WIJKSzVyPUG1NE43PiCwTR?=	M{C0WnNCVkeHUh?=
NCI-H661	M4TD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX33NlVSUUN3ME2xOVEvOjZibl2=	MV7TRW5ITVJ?
KYSE-70	NXPmOWxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jvbGlEPTB;MUWxMlc6KG6P	NF3VTGRUSU6JRWK=
SW900	NYTabWM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;icmlEPTB;MUW0MlY2KG6P	MXTTRW5ITVJ?
Ca-Ski	M1\LPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTF3Nj6zPUBvVQ>?	NGLGd5BUSU6JRWK=
HPAF-II	NFPmbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTF3Nj60O{BvVQ>?	M4\KcHNCVkeHUh?=
LB2518-MEL	M{C5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M363UmlEPTB;MUW3MlEhdk1?	M2TPVXNCVkeHUh?=
LC-2-ad	M2KwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfXbYZxUUN3ME2xOVgvPjJibl2=	NWnz[2lHW0GQR1XS
HCC1806	NIXEb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofiTWM2OD1zNkeuPFghdk1?	M1nEVXNCVkeHUh?=
UACC-62	NILYV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjkTWM2OD1zNkiuNFkhdk1?	MXzTRW5ITVJ?
KM-H2	M2T6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnqZ2tVUUN3ME2xO\|AvPThibl2=	MXvTRW5ITVJ?
NCI-H2347	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETMZYlKSzVyPUG3Nk44OiCwTR?=	NGfmcGxUSU6JRWK=
SCC-15	M1zTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF5Mz62OkBvVQ>?	M1vNV3NCVkeHUh?=
BB49-HNC	M3TBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXSNIxKSzVyPUG3N{45OSCwTR?=	M{\re3NCVkeHUh?=
GMS-10	M1fGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPyTWM2OD1zN{OuPVQhdk1?	NVWwNYx4W0GQR1XS
NCI-H2052	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPRTWM2OD1zN{SuPUBvVQ>?	M1XBNXNCVkeHUh?=
SW626	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTF5Nj6wOkBvVQ>?	MVrTRW5ITVJ?
MDA-MB-415	NFjiV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTF5Nj62NUBvVQ>?	MUTTRW5ITVJ?
Saos-2	NVfaZol2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHYTWM2OD1zN{muN\|Uhdk1?	MUfTRW5ITVJ?
DK-MG	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTF6MD6zJI5O	NHH1[ZlUSU6JRWK=
SNU-C2B	NVn5UXZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF6MD63N{BvVQ>?	Mlm0V2FPT0WU
A427	NFjGVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHkOndKSzVyPUG4Nk42PyCwTR?=	M4G2bXNCVkeHUh?=
KP-N-YS	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlSzTWM2OD1zOEWgcm0>	NITXZ3pUSU6JRWK=
J82	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\xPHh2UUN3ME2xPFUvOThibl2=	MUTTRW5ITVJ?
LS-411N	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYi3b5QzUUN3ME2xPFcvOjhibl2=	NETOU4pUSU6JRWK=
HCC1937	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTlbnZKSzVyPUG4O{41QSCwTR?=	NEH2dXhUSU6JRWK=
OE33	M3nmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\3b4VKSzVyPUG4PE46PyCwTR?=	MWLTRW5ITVJ?
NB7	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHDTWM2OD1zOEmuPFkhdk1?	M{HnNXNCVkeHUh?=
SW684	NHvmeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLleFJKSzVyPUG5Ok4yOyCwTR?=	MWPTRW5ITVJ?
HT-144	NHvOSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTF7Nj6xOUBvVQ>?	M4Kx[HNCVkeHUh?=
SK-MEL-30	M1vwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLmTWM2OD1zOU[uNkBvVQ>?	NFzt[5NUSU6JRWK=
DBTRG-05MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX74cm8zUUN3ME2xPVgvPDdibl2=	M1j4UHNCVkeHUh?=
NCI-H1395	M2jDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLaeFBSUUN3ME2xPVgvQDVibl2=	NV3yb45jW0GQR1XS
NCI-H2122	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\MfGtKSzVyPUKwNE42QSCwTR?=	M{jVPXNCVkeHUh?=
no-10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTH[YdOUUN3ME2yNFEvODRibl2=	M17tOXNCVkeHUh?=
SW48	NFL6fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;ybmlEPTB;MkCxMlMyKG6P	NGGwNYZUSU6JRWK=
NCI-H1650	M2\1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzB[IpKSzVyPUKwOE4xOSCwTR?=	NX6xTIZ7W0GQR1XS
MZ1-PC	NFvnWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3K[3Y4UUN3ME2yNFUvPThibl2=	NEHDUYNUSU6JRWK=
U-266	Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTJyNT63PUBvVQ>?	NFvHRZJUSU6JRWK=
CAS-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWf0N2JqUUN3ME2yNFcvPDRibl2=	MYDTRW5ITVJ?
AU565	NX75UGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJzMj64NkBvVQ>?	MVLTRW5ITVJ?
UACC-257	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[0TWM2OD1{MUOuPVkhdk1?	MmjjV2FPT0WU
CAL-27	M{HwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf1WFlKSzVyPUKxO{4xPSCwTR?=	NITqc4VUSU6JRWK=
NCI-H23	NF;mVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7DTWM2OD1{MUmuN\|Mhdk1?	MVXTRW5ITVJ?
TE-6	NXO4dYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT1bnZKSzVyPUKxPU43QCCwTR?=	MYHTRW5ITVJ?
TGBC24TKB	NXuzeI5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknrTWM2OD1{MkKuNVchdk1?	MUPTRW5ITVJ?
TE-1	M{HZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zhS2lEPTB;MkKyMlg5KG6P	MkT0V2FPT0WU
RCC10RGB	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\T[\|BPUUN3ME2yNlQvOTlibl2=	M3\T[XNCVkeHUh?=
NCI-H596	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnrc\|lWUUN3ME2yNlgvOjJibl2=	NV\GXpN4W0GQR1XS
SW954	NGWzOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3f3bWlEPTB;MkOzMlg{KG6P	M1f3fXNCVkeHUh?=
NCI-H2087	NYDHVHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfzNmJwUUN3ME2yN\|QvPTFibl2=	M2HFWnNCVkeHUh?=
SK-PN-DW	M{C4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJ\|NT6xPUBvVQ>?	MoPrV2FPT0WU
KM12	NIjWflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJ\|NT63JI5O	MXLTRW5ITVJ?
BT-474	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXMTWM2OD1{M{WuO\|Mhdk1?	MWrTRW5ITVJ?
IST-MES1	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\6TW5KSzVyPUKzOk42PyCwTR?=	NUXxVJFTW0GQR1XS
HT-1197	M1vEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfMVGVEUUN3ME2yN\|gvODlibl2=	MV\TRW5ITVJ?
CAL-54	NYn4[lhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ\|OD60PUBvVQ>?	MkHXV2FPT0WU
NB10	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1GzR2lEPTB;MkSwMlA3KG6P	MUPTRW5ITVJ?
PANC-10-05	M13OVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJ2NT61OkBvVQ>?	NIXwUYVUSU6JRWK=
NCI-H522	NX76ZZpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\vZmlEPTB;MkS4MlMyKG6P	NFTIPZdUSU6JRWK=
A388	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XjWmlEPTB;MkS5MlgzKG6P	MYrTRW5ITVJ?
GOTO	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLYSmY{UUN3ME2yOVAvOjlibl2=	NFTqSlNUSU6JRWK=
KLE	NHnRUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDV[oZKSzVyPUK1NU45PyCwTR?=	NGLybJhUSU6JRWK=
KYSE-520	NUHRU\|JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;4TWM2OD1{NUKuPFYhdk1?	MnWxV2FPT0WU
HCE-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXFfHJKSzVyPUK2Nk42KG6P	NWHLfYZMW0GQR1XS
KURAMOCHI	M{jGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vKeGlEPTB;Mk[1Mlkhdk1?	NXHBVYhrW0GQR1XS
HCC38	NIfZfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\NUWlEPTB;Mk[2MlQ5KG6P	MlLFV2FPT0WU
FADU	NVrue\|NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3yNGozUUN3ME2yOlYvPjNibl2=	MXzTRW5ITVJ?
CW-2	NVfldIFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jJUGlEPTB;Mk[5Mlk3KG6P	NUPDNlU5W0GQR1XS
L-428	NHK1cHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPJTWM2OD1{N{WuNVUhdk1?	MnTCV2FPT0WU
HCC1569	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTlepc6UUN3ME2yO\|UvQDRibl2=	NWLPXZQyW0GQR1XS
NCI-H810	NFK3RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInwOY5KSzVyPUK3PE4{OSCwTR?=	NFPsTYVUSU6JRWK=
LB771-HNC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP2cFlKSzVyPUK4OU45PCCwTR?=	M2SyVHNCVkeHUh?=
LCLC-103H	M2Lk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmqwTWM2OD1{OEWuPVkhdk1?	NGjoWGFUSU6JRWK=
EFO-21	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf1U2NKSzVyPUK4O{43QCCwTR?=	MX\TRW5ITVJ?
CAL-72	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TIOmlEPTB;MkmzMlE6KG6P	M1zZRnNCVkeHUh?=
SCC-9	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\RVG5KSzVyPUK5N{4zOiCwTR?=	MUfTRW5ITVJ?
COLO-829	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzzXGxMUUN3ME2yPVYvPSCwTR?=	NGXUbHdUSU6JRWK=
U-87-MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmq1TWM2OD1\|MECuO\|Mhdk1?	M2DIcXNCVkeHUh?=
MZ7-mel	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XyO2lEPTB;M{KzMlc3KG6P	Ml7rV2FPT0WU
NCI-H1770	NXjoUlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjKOXN4UUN3ME2zNlYvPzRibl2=	M2nJenNCVkeHUh?=
ChaGo-K-1	NYHsR5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX4TIxKSzVyPUOyPE4yKG6P	NIG1N5pUSU6JRWK=
SiHa	NW\Rdo5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nQUGlEPTB;M{K5MlI1KG6P	NFnCfZVUSU6JRWK=
NCI-SNU-5	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLLTWM2OD1\|M{[uO\|chdk1?	NFHoO3FUSU6JRWK=
DJM-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ftfmlEPTB;M{SwMlM{KG6P	MXfTRW5ITVJ?
OE19	MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHtTWM2OD1\|NECuOVMhdk1?	NF\KZZBUSU6JRWK=
NCI-H1651	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPhcWRKSzVyPUO0OE4yQCCwTR?=	NEjtcnhUSU6JRWK=
COLO-792	NGfwXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXmzNGRKUUN3ME2zOVQvPDJibl2=	M3KwSXNCVkeHUh?=
ACHN	NW\3dFNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTN3Nj63NUBvVQ>?	MnPHV2FPT0WU
TH-3	NVzHe3JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDXTYVFUUN3ME2zO\|kvQTVibl2=	NXHMSIxiW0GQR1XS
HT-1376	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17VN2lEPTB;M{i0Mlg5KG6P	M4\FfHNCVkeHUh?=
RH-18	NWXyUY1GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrJTWM2OD1\|OUSuO\|Qhdk1?	NHTydpFUSU6JRWK=
NB6	NIn0cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnL3TWM2OD1\|OU[uOlYhdk1?	MX7TRW5ITVJ?
COLO-320-HSR	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTRyMz6zO{BvVQ>?	Mn[2V2FPT0WU
UACC-893	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGL5RlJKSzVyPUSwOk41PyCwTR?=	NFXFTnRUSU6JRWK=
DSH1	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfxRlNwUUN3ME20NFYvQTFibl2=	MWfTRW5ITVJ?
TE-10	M{TiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O4fmlEPTB;NEC3MlAyKG6P	Mn24V2FPT0WU
HCC70	M{jodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXxTWM2OD12MEmuNlEhdk1?	NYHsWWRCW0GQR1XS
TGBC11TKB	NG\hb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1WwSmlEPTB;NEGwMlM{KG6P	NGDld5VUSU6JRWK=
NCI-H727	NHHZWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17VU2lEPTB;NEGyMlEyKG6P	NHHVOVBUSU6JRWK=
ALL-PO	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1O4dWlEPTB;NEG1MlY6KG6P	M1rq[HNCVkeHUh?=
ABC-1	Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O4NWlEPTB;NEKwMlQ2KG6P	NIPKbm9USU6JRWK=
NCI-H69	M2K5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPYTWM2OD12Mk[uO\|Yhdk1?	NX70SIJ3W0GQR1XS
GP5d	M1y2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHLTWM2OD12M{SuOFEhdk1?	NEDrWVBUSU6JRWK=
UMC-11	NGDlUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfwVGlvUUN3ME20OVgvOzZibl2=	Mn73V2FPT0WU
RMG-I	MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofZTWM2OD12NkeuOVYhdk1?	MljZV2FPT0WU
YAPC	NGLxbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYj1dZZOUUN3ME20PVAvPiCwTR?=	M1;y[3NCVkeHUh?=
LS-1034	M4\PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\idHNpUUN3ME20PVEvODZibl2=	NFz6XYlUSU6JRWK=
RCM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXIXFF7UUN3ME20PVYvPjhibl2=	M3e2RnNCVkeHUh?=
HCC1954	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\CTWM2OD13MUKuOUBvVQ>?	NH\kNGZUSU6JRWK=
SK-MEL-24	M1vDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3yTWM2OD13MU[uOVEhdk1?	NET6N5VUSU6JRWK=
NB12	NUPRe2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXQSmtKSzVyPUWyPE41OiCwTR?=	MVzTRW5ITVJ?
SW756	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTV3ND65OkBvVQ>?	M{LyW3NCVkeHUh?=
HCC1187	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfRSGlKSzVyPUW3OU45OyCwTR?=	NW\xUm9lW0GQR1XS
NCI-H2342	NVPlToQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLuTWM2OD13OUCuN\|khdk1?	M4PRU3NCVkeHUh?=
NCI-H2291	NUPJeoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTYVFFPUUN3ME21PVgvOzFibl2=	MX7TRW5ITVJ?
OVCAR-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\GTXJkUUN3ME21PVgvQTZibl2=	NGTzcYNUSU6JRWK=
MHH-NB-11	NIT5UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NES3eIpKSzVyPU[yPU4xOSCwTR?=	NWXZc2xjW0GQR1XS
SAS	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf0TWM2OD14NUKuOlchdk1?	M{K2OXNCVkeHUh?=
COLO-824	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTZ6OT6zO{BvVQ>?	NVHyc\|dlW0GQR1XS
HCC1395	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[yR2lEPTB;Nkm4MlUhdk1?	MYfTRW5ITVJ?
COLO-668	NV;WTJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Lse2lEPTB;N{C2MlEhdk1?	NUHQOGxDW0GQR1XS
NCI-H226	M3ixeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjyOnlJUUN3ME23NFcvQCCwTR?=	MVXTRW5ITVJ?
NB17	NXvkOHlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3yzT2lEPTB;N{KxMlc2KG6P	NVX5XlJNW0GQR1XS
SW1463	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILYTm1KSzVyPUezPU4yQSCwTR?=	Mnn0V2FPT0WU
TGW	NILq[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7rVXhVUUN3ME23OlAvOTVibl2=	MV7TRW5ITVJ?
NCI-H526	NELp[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\MTlZKSzVyPUiyN{42OyCwTR?=	NYDo[VRTW0GQR1XS
COR-L88	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTh2OD6xNkBvVQ>?	MXrTRW5ITVJ?
NCI-H441	NX65UZQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[0TWM2OD16OUWuNlIhdk1?	MmHRV2FPT0WU
NCI-H630	M1PJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTlzMj65OkBvVQ>?	NIfWSmpUSU6JRWK=
Mo-T	M4nU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXmRWlpUUN3ME25OFcvQDhibl2=	M{X1OnNCVkeHUh?=
JAR	NF72WndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P1TWlEPTB;OUW2MlI1KG6P	M1XZZXNCVkeHUh?=
NCI-H1838	M33Mcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXGOpBKSzVyPUGuNFI{QDhizszN	NIrWUVBUSU6JRWK=
DoTc2-4510	NGPHSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFwMEezO\|Yh\|ryP	MVvTRW5ITVJ?
MKN28	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm0d3ZQUUN3ME2xMlA6ODJ2IN88US=>	MlTsV2FPT0WU
HuP-T3	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7iTWM2OD1zLkGxPVA2KM7:TR?=	M{j2RXNCVkeHUh?=
TE-9	M2\hSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmW0TWM2OD1zLkGyPVc{KM7:TR?=	MlixV2FPT0WU
NY	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfSVVFKSzVyPUGuNVY4QTJizszN	NHrMeGhUSU6JRWK=
HT55	NVfzTHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHWzbG9KSzVyPUGuN\|E{PDRizszN	Mme4V2FPT0WU
SW837	NYLRfG5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwM{K5O\|gh\|ryP	MYnTRW5ITVJ?
NCI-H2029	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwNEG3PVEh\|ryP	NGXX[plUSU6JRWK=
IST-SL1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrxd3dKSzVyPUGuOFQzPCEQvF2=	MXjTRW5ITVJ?
COLO-741	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTFwNEm3O\|Eh\|ryP	NG[2T4lUSU6JRWK=
LU-65	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3O4XGlEPTB;MT62NlI1QSEQvF2=	NGXmOYZUSU6JRWK=
NCI-H1304	M1LuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3KTWM2OD1zLk[1OFk5KM7:TR?=	M3XPSnNCVkeHUh?=
KARPAS-299	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M333OGlEPTB;MT63PVQ4QSEQvF2=	NITFfoxUSU6JRWK=
NCI-H358	NIC0R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfIfIZ5UUN3ME2xMlk2PTB\|IN88US=>	NXT4dmppW0GQR1XS
OAW-28	NFT0NnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTJwME[5NVkh\|ryP	Ml20V2FPT0WU
C8166	NVL1[odLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTGXFJVUUN3ME2yMlY{Ozl{IN88US=>	M1vzd3NCVkeHUh?=
COLO-678	NV62[5FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3hTWM2OD1{LkizO\|Y5KM7:TR?=	NUfqTFNUW0GQR1XS
SK-N-DZ	M2jyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzLT4JKSzVyPUKuPFY{QDFizszN	MlnCV2FPT0WU
NCI-H82	NWfEfVh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnlTWM2OD1{LkmwN\|Y6KM7:TR?=	NIj5R3lUSU6JRWK=
JVM-2	NEi0U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T0ZmlEPTB;Mz6wN\|E5QCEQvF2=	NWWwUWVyW0GQR1XS
SW1116	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTNwMEW0NVEh\|ryP	MoW5V2FPT0WU
MDA-MB-453	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTVXVRKSzVyPUOuNVA1OzlizszN	NIn1U2dUSU6JRWK=
Calu-6	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVf3SJY3UUN3ME2zMlE6QTdizszN	M3HURXNCVkeHUh?=
SHP-77	M2\wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;GTWM2OD1\|LkWyPEDPxE1?	NX;tfWx6W0GQR1XS
Capan-2	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfWOllKSzVyPUSuN\|I2QDFizszN	NUDPNIlVW0GQR1XS
SW948	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTRwN{S3O\|kh\|ryP	MlSwV2FPT0WU
HDLM-2	M2PpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjpO4RKSzVyPUWuNFc4OjVizszN	M3jSNXNCVkeHUh?=
LAN-6	M3T0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf0d5ZSUUN3ME22MlIyPDl3IN88US=>	MVHTRW5ITVJ?
LU-135	NVPYfnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTZwNEOwO\|ch\|ryP	NFThTm1USU6JRWK=
T84	M3O0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2n4UmlEPTB;Nj65PFY1KM7:TR?=	NUXZd4F{W0GQR1XS
CAPAN-1	M33SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrud4VKSzVyPUeuOlIzOzNizszN	M4PzWXNCVkeHUh?=
SW1417	NVLiSYxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTFTWM2OD15LkmxO\|MyKM7:TR?=	MVPTRW5ITVJ?
BALL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XNTWlEPTB;OD61NFQxQSEQvF2=	M{fJS3NCVkeHUh?=
HT-29	NXXReWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvHPWw6UUN3ME25MlA4PTl7IN88US=>	NYjFbYtTW0GQR1XS
C3A	NWqye\|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTWSGhKSzVyPUmuPFg{QTRizszN	Mo[1V2FPT0WU
NCI-H1993	NVnFW4RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFq3WFZKSzVyPUGwMlUxQDFizszN	NXLIT45HW0GQR1XS
SK-MEL-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfTTWM2OD1zMT62Nlg6KM7:TR?=	NW\0dG1GW0GQR1XS
DU-145	NUDLOVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TId2lEPTB;MUSuOVA2OiEQvF2=	NUXNO4xWW0GQR1XS
KP-N-YN	NVGxUIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPTdm1KSzVyPUG0MlUyODNizszN	M4T5XnNCVkeHUh?=
CCRF-CEM	M176OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTF2Lke4NFkh\|ryP	MmHCV2FPT0WU
ZR-75-30	NIDUVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:wVmFKSzVyPUG2MlM{ODNizszN	NVnSSFdTW0GQR1XS
A673	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{n2RmlEPTB;MkCuOVUxPyEQvF2=	Mm\iV2FPT0WU
K-562	M33ZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnq0TWM2OD1{OD60NVg{KM7:TR?=	NXvGT3BuW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01482156	Completed	Drug: RAD001 + BEZ235	Advanced Solid Tumors\|Metastatic Breast Cancer\|Metastatic Renal Cell Carcinoma	Novartis Pharmaceuticals\|Novartis	January 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 221 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 221 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)